Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

BACKGROUND: Precision medicine trials disrupted the paradigm of randomized controlled trials in large populations. Patient selection may be based on molecular alterations rather than on primary tumor location. In small patient populations, the growth modulation index (GMI) has been developed to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: du Rusquec, P., Guimbaud, R., Le Malicot, K., Gornet, J.-M., Nguyen, S., Lecomte, T., Khemissa-Akouz, F., Perrier, H., Bouché, O., Paoletti, X., Le Tourneau, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485393/
https://www.ncbi.nlm.nih.gov/pubmed/37542912
http://dx.doi.org/10.1016/j.esmoop.2023.101616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485393/
https://www.ncbi.nlm.nih.gov/pubmed/37542912
http://dx.doi.org/10.1016/j.esmoop.2023.101616

Ejemplares similares